Murdoch Children's Research Institute, Australia
Talk Title: New approaches to measuring barriers to immunisation, developing evidenced-based interventions and evaluation of vaccine policy in Australia
Margie is a senior research fellow at the MCRI and a consultant paediatrician at the Royal Children’s Hospital, Department of Paediatrics. She has extensive expertise in vaccine research focused on clinical trials, vaccine safety and vaccine social science.
View full bio
Her primary research focus has shifted to developing new interventions to improve vaccine confidence and uptake amongst different populations and in different settings, including pregnancy, primary care, for high risk children and in developing country settings. She aims to provide a solid evidence base to inform vaccine policy in Australia to support the least restrictive vaccine mandates that will still ensure high vaccine coverage for Australian children. Margie is now a trusted and public face of vaccine confidence and acceptance in Australia with a prominent role in the media. She has international collaborations with leading researchers in the area and is invited to speak at national and international conferences on vaccine confidence.
World Health Organization, Switzerland
Talk Title: Disease eradication in human populations: challenges and opportunities
View full bio
More information coming soon
Jose de la Fuente
SaBio. Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM-JCCM), Spain and Oklahoma State University, USA
Talk Title: Targeting host-vector-pathogen interactions to reduce the global burden of vector-borne diseases
José de la Fuente Graduated in Physics at Moscow State University and University of Havana in 1984. Ph.D. in Biology at University of Havana.
View full bio
Current position: Professor, SaBio, Instituto de Investigación en Recursos Cinegéticos IREC (CSIC-UCLM), Spain and Adjunct Professor, Department of Veterinary Pathobiology. Center for Veterinary Health Sciences, Oklahoma State University, U.S.A. Head of the Genomics, Proteomics & Biotechnology Lab. Thirty-three years experience in research, education and as Principal Investigator in research projects. Over 600 published papers in international journals and 5 books in areas of basic molecular biology and biotechnology. Patents: 30. PhD thesis supervised: 32. Current Research Interests: Infectious diseases. Molecular biology of host-vector-pathogen interactions, gene regulation, pathogenesis, functional genomics, evolution and immunology. Systems biology. Ticks and tick-borne diseases. Intracellular bacteria (Rickettsia, Anaplasma, Mycobacterium). Vaccinology. Biotechnology.
Google scholar profile: http://scholar.google.com/citations?user=Cu4qOlgAAAAJ&hl.
ResearchGate profile: https://www.researchgate.net/profile/Jose_De_la_Fuente/?ev=hdr_xprf.
Icahn School of Medicine at Mount Sinai, New York, USA
Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna, Austria. He received his postdoctoral training in the laboratory of Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines.
View full bio
In 2013 he became an independent principal investigator and is currently Associate Professor at the Icahn School of Medicine at Mount Sinai. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on Zika virus, hantaviruses, filoviruses and arenaviruses.
University of Colorado Anschutz Medical Campus, USA
Talk Title: Recombinant Glycoprotein E Adjuvanted Herpes Zoster Vaccine
Myron Levin graduated from Harvard Medical School in 1960. He completed a residency in Internal Medicine at the Bronx Municipal hospital Center (Einstein Medical School), and spent the next three years at the National Institutes of Health; the last two years at NIH were devoted to research in molecular virology.
View full bio
Dr. Levin returned to Harvard in 1969 to complete a fellowship in Infectious Diseases with the combined adult-pediatric training program at the Children’s Hospital and the Beth Israel Hospital, and remained as the first Chief of Infectious Diseases at the Sidney Farber Cancer Center (now the Dana-Farber Cancer Institute).
From 1982 to 2000 he was Chief of Pediatric Infectious Diseases at the University of Colorado School of Medicine and the Children’s Hospital of Denver, and Director of the Clinical Virology Laboratory at the University of Colorado Hospital. He is a Professor of Pediatrics and Medicine. Dr. Levin directs a clinic for research on experimental vaccines and antiviral drugs, and maintains the HIV clinic for children and pregnant women at Children’s Hospital Colorado.
Dr. Levin’s clinical interests are in antiviral therapy, the immune response to herpesvirus infections, and vaccine science. His laboratory studies focus on latency of herpesviruses in human neurons, and the nature of latent herpesviruses in human ganglia. Clinical studies focus on the immune response to established and experimental vaccines and correlates of protection, especially in older vaccinees. Dr. Levin was a member of the Advisory Committee on Immunization Practices (CDC) for 5 years, serving as its Chair for the last 2 years. Dr. Levin has authored >425 original articles and edited 14 books.
Dr. Andrew Potter is a graduate of Carleton University (Canada) and the University of Otago (New Zealand) and has worked at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, for the past 33 years serving as a research scientist, Associate Director (Research) and most recently, Director and CEO.
View full bio
His primary research interests are in the areas of the pathogenesis of bacterial respiratory diseases and the development of vaccines for zoonotic diseases. He has previously held an NSERC Senior Industrial Research Chair in the area of vaccine development for food and water safety pathogens. Dr. Potter has mentored more than 49 graduate students and post-doctoral fellows who currently hold positions in industry, academia and government worldwide, and he has contributed to more than 65 patents for human and animal vaccines and therapeutics.
He was also a founding Director and former CEO of the Pan-Provincial Vaccine Enterprise (PREVENT), a National Centre of Excellence in Commercialization and Research funded by the National Centres of Excellence Program of the Federal Government.
Dr. Potter has served on a number of public and private sector committees and Boards, and has been instrumental in transferring VIDO-InterVac technology from the laboratory to the private sector, including five vaccines he developed or co-developed. Dr. Potter has received a number of awards for his work, the most recent being the SHRF Career Achievement Award.
Julius Global Health University Medical Center, The Netherlands
Talk Title: The ADVANCE system for monitoring benefits and risks of vaccines in EU
Miriam Sturkenboom is a pharmacoepidemiologist, currently working at the Julius Global Health group of University Medical Center Utrecht in the Netherlands after having spent 20 years in the department of Medical Informatics at Erasmus MC.
View full bio
She is president of the VACCINE.GRID foundation that promotes global research into the effects of vaccines. She is past president of the International Society for Pharmacoepidemiology. She serves as expert to EMA, FDA, WHO and many other organizations.
Her research interests focus on knowledge discovery from data collected in routine health care to improve evidence on drug and vaccine safety in particular in vulnerable populations (children, pregnancy and elderly). She is coordinator of the European commission funded ADVANCE project aiming to establish a tested system for the monitoring of benefits and risks of vaccines. She pioneered and implemented the data managament and data sharing infrastructures for large collaborative distributed data network studies to allow for European vaccines safety studies during the pandemic VAESCO) and global vaccine and drug studies (SOMNIA, GVS-MCC). In terms of quantitative research outputs: she supervises/d more than 50 PhD students, has more than 380 peer reviewed papers in the area of pharmacovigilance, pharmacoepidemiology and medical informatics and an h-index of 70.
More speakers coming soon.